Oncology Institute (TOI)

Executive Summary

The Oncology Institute, Inc. (NASDAQ: TOI) is a publicly traded community oncology practice that delivers integrated cancer care through a value-based model, tying reimbursement to patient outcomes and cost efficiency. Operating in the United States, the company provides medical oncology, hematology, radiation oncology, and ancillary therapies outside of major hospital systems. A key differentiator is its dedicated clinical research division, which enables patients to access novel therapies through community-based trials. As a public company, its performance is closely monitored via SEC filings. The Oncology Institute's approach aims to manage total cost of care while expanding access in community settings, positioning it as a unique player in the oncology services and biotech sectors.

Upcoming Catalysts (preview)

• Q2 2026Q2 2026 Earnings Report - Potential growth in value-based contracts65% success
• Q3 2026Expansion into new geographic markets through partnerships50% success
• Q4 2026Announcement of new clinical trial collaborations or drug approvals40% success